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ABSTRACT
Huntington’s disease (HD) is a fatal, neurodegenera-
tive disorder in which patients suffer from mobility,
psychological and cognitive impairments. Existing
therapeutics are only symptomatic and do not sig-
nificantly alter the disease progression or increase
life expectancy. HD is caused by expansion of the
CAG trinucleotide repeat region in exon 1 of the
Huntingtin gene (HTT), leading to the formation of
mutant HTT transcripts (muHTT). The toxic gain-of-
function of muHTT protein is a major cause of the
disease. In addition, it has been suggested that the
muHTT transcript contributes to the toxicity. Thus,
reduction of both muHTT mRNA and protein levels
would ideally be the most useful therapeutic option.
We herein present a novel strategy for HD treatment
using oligonucleotides (ONs) directly targeting the
HTT trinucleotide repeat DNA. A partial, but signifi-
cant and potentially long-term, HTT knock-down of
both mRNA and protein was successfully achieved.
Diminished phosphorylation of HTT gene-associated
RNA-polymerase II is demonstrated, suggestive of
reduced transcription downstream the ON-targeted
repeat. Different backbone chemistries were found
to have a strong impact on the ON efficiency. We
also successfully use different delivery vehicles as
well as naked uptake of the ONs, demonstrating ver-
satility and possibly providing insights for in vivo
applications.
INTRODUCTION
Huntington’s disease (HD) is a fatal, neurodegenerative
disorder affecting the striatum, cerebral cortex and other
subcortical structures. HD onset appears around midlife
in most cases, and is characterized by a combination
of symptoms: movement abnormalities, emotional distur-
bances and cognitive impairments (1). The most character-
istic feature in HD patients is the uncoordinated irregular
movements, known as ‘chorea’ (Greek for: dance); however,
this is usually preceded by psychiatric symptoms and cogni-
tive problems. In most cases, HD symptoms begin at 35–50
years of age and end with death 15–20 years later (2). De-
spite the identification of the genetic cause of HD in 1993
(3), no curative therapy has yet been developed. Current
pharmaceuticals can only provide symptomatic ameliora-
tion but fail to treat the underlying cause or stop disease
progression (4).
HD is caused by a polyglutamine-encoding CAG trinu-
cleotide repeat expansion in exon 1 of theHuntingtin (HTT)
gene leading to the formation of mutant HTT (muHTT)
protein. The number of the repeats in the mutant allele in-
versely correlates with the age of onset. The prevalence of
HD is one of the highest among themonogenic neurological
disorders in the developed world affecting 10–12 in 100 000
people (5). In HD there is a gain-of-function of the muHTT
protein (6), while the loss of wild-type HTT (wtHTT), to
certain extent, was proven to be safe (7,8). Complete loss of
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wtHTT during embryonic development is lethal (9), while
decreasing wtHTT levels in adult animals seems to be well
tolerated (10,11). Encouragingly, in a human embryonic
stem cell-derived neuronal model, a 10–20% reduction of
themuHTT alone was sufficient to show a significant reduc-
tion of toxicity, whereas reducing wtHTT by up to 90% was
described as safe (12). In addition, studies in Rhesus mon-
keys showed that a 45% reduction in the putamen resulted in
no mobility or neurotoxic effects during the 6 weeks follow
up (13). Interestingly, humans with a heterozygous translo-
cation interrupting the HTT gene and who have reduced
levels of HTT displayed no phenotypic abnormality (5,7,8).
Altogether, loweringmuHTT at the expense of a partial loss
of wtHTT may be acceptable in a clinical context for adult
patients.
There is increasing evidence that muHTT transcripts also
contribute to HD toxicity (14,15). RNA-related toxicity
mechanisms have not been equally explored as those related
to the muHTT protein although both add to the overall
pathogenic gain-of-function effect (16,17). CAG-expanded
HTT transcripts were shown to be retained in the nucleus
of human HD fibroblasts and to co-localize with a splicing
factor involved in the pathogenesis of CTG/CAG expanded
transcripts (18,19). Moreover, the CAG repeat transcripts
were demonstrated to form secondary structures that can
be cleaved byDicer resulting in aberrant generation of short
repeatedRNA (20,21). The latter was proven to cause inher-
ent toxicity in a neuronal cell model (14), potentially con-
tributing to the disease phenotype.
The monogenic origin of HD makes it an appealing tar-
get using oligonucleotides (ONs) that can affect the HTT
gene expression. Different ON strategies, indeed, have been
applied for targeting HTT such as siRNAs (22), splice-
switching ONs (23), single nucleotide polymorphism (SNP)
- targeting ONs (24), zinc finger nucleases (25) and anti-
sense ONs working via either RNase-mediated degradation
(26) or steric blocking of the HTT mRNA. Previous trials
for blocking HTT with ONs can be categorized, accord-
ing to their objective, into two main classes: allele-specific
and non-allele specific strategies. Allele-specific silencing
has been successfully achieved via antisense ONs that can
hybridize to theHTTmRNAand by steric blocking prevent
its translation. Such ONs, due to the difference in stabil-
ity possessed by the mutant and wild-type RNA structures,
could bind better to the muHTT mRNA (27). This ap-
proach was successfully achieved using antisense ONs with
different chemistries (28–30), single-strandedRNAs (31,32)
and siRNAs with mismatches (33–35), which improved the
mutant selectivity over the wild-type. ONs working by this
strategy will not decrease the HTT mRNA levels (29,33).
Alternatively, when the CAG tract expansion is linked with
SNPs that can be targeted by gene silencing ONs, allele-
specificHTT reduction can be accomplished (36). SNP tar-
geting was first achieved using siRNAs (37), and subse-
quently various antisenseONswith different chemicalmod-
ifications have shown great success (38,39). To use this ap-
proach, prospective treatments need to be tailored to each
group of individuals that carry the same SNP.
The non-allele specific approach has been recently sug-
gested as a valid and safe option that would avoid the time-
consuming and costly individualized therapy (40,41). Non-
allele specific targeting has been achieved using antisense
ONs targeting outside the trinucleotide repeat region and
inducing degradation ofHTTmRNA via RNase H recruit-
ment (26). Furthermore, a number of siRNAs has been de-
veloped to efficiently degrade theHTTmRNAvia theRNA
interference process (42). In fact, non-allele specific down-
regulation can be considered successful as long as the level
of wtHTT remains above the threshold required for normal
cell function (10,11,43).
We reasoned that if both polyQ-expanded HTT protein
and its transcript are neurotoxic, achieving a specific down-
regulation without involvement of RNA degradation, while
keeping the wtHTT to the acceptable safe thresholds, could
be an attractive therapeutic option. ONswere designedwith
the aim of binding to the HTT gene and block its tran-
scription. Interfering at the DNA level would provide a par-
tial, but potentially long-term down-regulation, which in
turn could decrease the dose needed. We designed ONs as
mixmers of DNA or 2′-O-methyl-RNA with locked nucleic
acid (LNA) (44), which have shown previously to improve
the capacity of strand-invasion into double-stranded DNA
(dsDNA) (45), and in one construct also including novel 2′-
glycylamino-LNAs.
In this work, we report an LNA/DNA ON-based strat-
egy, where the drug successfully binds to theHTT gene tem-
plate strand down-regulating mRNA and protein levels in
HD patient fibroblasts. Reduction of HTT protein is shown
to last for 10 days, which was the longest time assayed in
the study. RNA polymerase II serine 2 phosphorylation is
significantly impaired at the HTT gene supporting an ON
effect on gene expression at the transcriptional level. In ad-
dition, we address the possibility to use cell penetrating pep-
tide (CPP)-based delivery and also naked uptake, known as




LNA/DNAONs were either bought from Eurogentec (Bel-
gium) or synthesized at Nucleic Acid Center, University of
Southern Denmark. CAG ONs were designed to target the
DNA template strand while CTG ONs (13, 13gap and 19)
were designed to target the mRNA and used as controls.
CAG ONs were synthesized in different lengths ranging
from 10- to 19-mers. The 12-, 13- and 14-mer CAG ONs
were synthesized in both phosphodiester (PO) and phos-
phorothioate (PS) backbone format. The 14-mer CAG PS
ON was synthesized either as an ON including 2′-O-methyl
RNA /LNA, namely: CAG-14PS-OMe or as a CAG-14PS-
gly ON where 5-methylcytosine-2′-glycylamino-LNA sub-
stitutes the regular cytidines (see Supplementary Methods
for Synthesis Details (47)). A number of mismatched and
scrambled ONs were used as controls (sequences found in
Table 1). An siRNA targeting HTT transcripts outside the
repeat region, and used previously (33,48), was obtained
from Sigma. A complete list of the ON sequences can be
found in Table 1.
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Table 1. ONs used in the study. CAG ONs are designed to target the template strand of theHTT gene while CTG ONS are designed to target the mRNA
and used here as controls. All the ONs used in the study have PS backbone. The CAG-12, -13 and -14 are made in two different versions, one with PO and
the other with PS backbone. LNA bases are written in capital letters while DNA in small. In the ON CAG-14PS-OMe, the 2′-O-methyl RNA bases are
superscripted with ‘m’. In the ON CAG-14PS- gly, the 2′-glycylamino 5′-methylcytosine LNA nuccleotides are superscripted by ‘gly’
ONs Sequence
CAG-10PS 5′-cAgCAgCAgC
CAG-12PS and CAG-12PO (both Cy5 labelled) 5′-cAgCAgCAgCAg
CAG-13PS and CAG-13PO (both Cy5 labelled) 5′-cAgCAgCAgCAgc








Scramble ON1 (scramb.1) 5′-gACgACgACgACgA
Scramble ON2 (scramb.2) 5′-gAcGAcGAcGAcGA
Mismatched ON1 (mismatch.1) 5′-aAgAAgAAgAAg
Mismatched ON2 (mismatch.2) 5′-aAgAAgAAgAAgAA
Mismatched ON3 (mismatch.3) 5′-cAaCAgCAgCAaCAgCAa
Control CTG-13PS 5′-cTgCTgCTgCTgc




Cell culture, transfections and gymnosis
Huntington patients’ primary fibroblasts GM04281,
GM09197 and GM04022 were obtained from the Coriell
Cell repositories. GM04281, GM09197 and GM04022
HD fibroblasts in this order have numbers of 68/17,
151/21 and 44/12 trinucleotide repeats representing the
mutant/wild-type HTT, respectively. Fibroblasts were
grown in Dulbecco’s Modified Eagle Medium with L-
glutamine, pyruvate and low glucose (Invitrogen, Sweden),
supplemented with 10% fetal bovine serum (Invitrogen).
Fibroblasts weremaintained at 37◦C, 5%CO2 in humidified
incubators. One day prior to transfection, fibroblasts were
seeded at 30 000 cells per well in a 24-well plate or at 160
000 cells per well in a 6-well plate. ONs were formulated
either with lipofectamine RNAiMAX® (RNAiMAX)
according to the manufacturer’s protocol or with the CPP
Pepfect 14 (PF14) in a molar ratio 1:5 (ON: peptide).
Formulations were added to the fibroblasts, while still
growing in 10% fetal bovine serum medium, to give a
100 nM final concentration of the ON. Gymnosis was
performed by adding the ONs directly to the cells one day
after seeding without using transfection reagents. Unless
otherwise stated, cells were cultured for four days following
transfections or kept under gymnosis for four days, after
which the cells were lysed for RNA or protein assessment.
For the 7- and 10-day cultures, more medium was added to
the cells.
Fluorescence microscopy
Cy5 labeled ONs were transfected into GM04281 fibrob-
lasts at 100 nM concentration using RNAiMAX. Before
imaging, the medium was aspirated and cells were carefully
rinsed using fresh full medium to ensure the removal of any
ON or formulation residuals. Live cells were then imaged
using a fluorescence microscope (Olympus IX81, Olympus
America Inc.) and the signal of the Cy5-labeled ONs was
detected.
RNA isolation and quantitative reverse transcriptase multi-
plex PCR (qRT-PCR)
At specific time points, cells were lysed and total RNA iso-
lated using the RNeasy plus kit (QIAGEN, Sweden). RNA
was analyzed using multiplex q RT-PCR to amplify both
HTT and HPRT1 as an endogenous control. This assay
was performed using the Quantifast® Multiplex RT-PCR
kit (Qiagen). Sequences of primers and probes for HTT
and HPRT (Sigma) were as follows: HTT-fwd: 5′- gactc-
gaacaagcaagag, HTT-rev: 5′-gcctttaacaaaaccttaatttc,
HPRT-fwd: 5′- gagctattgtaatgaccagtc, HPRT-rev:
5′-tgaccaaggaaagcaaag, HTT taqman probe: 5′-
[JOE]gaagaatcagtccaggagacc[BHQ1] and HPRT taqman
probe: 5′- [6FAM]tgccagtgtcaattatatcttccacaa[BHQ1]
where JOE and 6-FAM are two fluorophores having
different emission spectra and with Black Hole Quencher
(BHQ1) used as quencher. Multiplex qRT-PCR reaction
setup was done according to the Quantifast® kit protocol,
where 35 ng of RNAwas used for all reactions and the final
volume of each reaction was 25 l. Standard curves were
made using known amount of RNA and serially diluted in
order to confirm the efficiency of PCR, which was close to
100%. Cycling conditions of PCR were: 20 min 50◦C for
reverse transcription, 5 min 95◦C for PCR initial activation
step and 45 cycles, each of 2 steps: 15 s, 95◦C denaturation
and 30 s, 60◦C for annealing/extension. Quantitative RT-
PCR was performed using the StepOnePlus® Real time
PCR system (Applied Biosystems, Sweden) and the data
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were analyzed by the Ct method using the StepOne®
software version 2.2.
Western blotting
Cells in the 6-well plates were lysed using amixture of RIPA
lysis buffer andNuPAGE® LDS sample buffer (Invitrogen)
in a ratio of 3:1, respectively. The plates were kept on ice
for 30 min, and then the lysates were transferred to Eppen-
dorf tubes, which were shaken for 30 min at 4◦C to ensure
cell lysis. Four microliters of NuPAGE® sample reducing
agent 10x (Invitrogen) were added to 40 l cell lysate and
the mixture was heated to 95◦C for 5 min just before load-
ing on the gel. Proteins were separated on NuPAGE® 3–
8% tri-acetate gels at 70 V for 25 min followed by 125 V
for 6 h and the whole electrophoresis procedure was per-
formed on ice at 4◦C. The gels were then transferred onto
nitrocellulose membranes using the IBlot® system (Invit-
rogen) and subsequently the membranes were blocked with
Odyssey Blocking Buffer (LI-COR Biosciences GmbH) for
1 h. Membranes were probed using anti-HTT primary an-
tibody (MAB2166, Millipore) and anti-importin 7 anti-
body, which was used as a housekeeping control, diluted
at 1:500 and 1:1000, respectively, over night. Signals were
detected after soaking with secondary antibodies, which
were goat anti-mouse and goat anti-rabbit for HTT and im-
portin 7, respectively. For checking the expression of control
genes containing CAG repeats, NuPAGE® Bis-Tris 4–12%
gels were used to separate the proteins. After transfer and
blocking as described, the membranes were probed with
monoclonal Anti-TBP (Tata box binding protein) (Sigma)
1:2000, polyclonal Anti-FOXP2 (Forkhead box protein P2)
(Abcam) 1:1000 and polyclonal Anti-ATN1 (Atrophoin-1)
(Santa Cruz) 1:1000. All Western blot signals were scanned
using the Odyssey Imager (LI-COR Biosciences GmbH).
Thermal UV-melting experiments
All Tm experiments were performed using a Varian Cary
300 UV-VIS spectrophotometer. The ON concentrations
used were 3 M each in a total volume of 400 l contain-
ing intra-nuclear salt buffer (Tris-acetate 50 mM (pH 7.4),
120 mM KCl, 5 mM NaCl, 0.5 mM Magnesium acetate).
The melting profile started at 95◦C and was followed down
to 20◦C at 0.2◦C/min, and returning to 95◦C at the same
rate. Absorbance was recorded at 260 nm and Tm calcu-
lated from processed curves using the instrument software
algorithms.
Plasmid cloning and hybridization experiments
Plasmid 1735-1 contains a 72 CAG repeat sequence (216
bp) andwas generated byMutagenex using standardmolec-
ular cloning procedures. The control plasmid contains the
same backbone, but lacks the trinucleotide repeat region.
ONs and plasmids were hybridized for 72 h at 37◦C in 10 l
using 500 ng of plasmid and 40 pmol of ON in intra-nuclear
salt buffer, unless otherwise stated.
Restriction enzyme assay of ON target binding
Restriction enzymes AvrII (#FD1564) and HindIII
(#FD0504) (Thermo Scientific) were incubated with 500 ng
plasmid 1735-1 (pre-incubated 24 h with or without 4 M
CAG-ONs), according to the manufacturer’s protocol. The
samples were analyzed by polyacrylamide gel electrophore-
sis using 20% polyacrylamide gels in TBE (Tris borate
ethylenediaminetetraaceti cacid) (Life Technologies). An
amount of 200 ng of DNA in DNA Loading Dye buffer
(Thermo 6x R0611 diluted to 1x in ddH2O) was loaded into
each well. Electrophoresis was performed at 110 V for 1.2 h
in 1xTBE buffer. The gel was stained using 1xSYBRGold
nucleic acid gel stain (Invitrogen #S-11494) for 7 min on
shaker, visualized using a VersaDoc system (BioRad) and
analyzed by the QuantityOne software (BioRad).
Chromatin Immunoprecipitation (ChIP-qPCR)
ChIP-qPCR was performed using the iDEAL ChIP-seq kit
for histones (Diagenode) according to the manufacturer’s
instructions. Briefly, cells (transfected with either CAG-
19PS or scrambled ON2) were fixed in 1% formaldehyde for
8 min, and following chromatin extraction aliquots of one
million cells, were sonicated for 12 cycles of 30 s on/off in 1.5
ml Bioruptor Microtubes (Diagenode) 1.5 ml tubes with a
Bioruptor pico (Diagenode). Onemillion cells were used per
immunoprecipitation with 3 g of antibodies against ac-
tive histone modifications: histone 3 lysine 4 trimethylation
(H3K4me3) (Ab-003-050, Diagenode) and histone 3 lysine
27 acetylation (H3K27ac) (ab4729,Abcam) or 5g ofRNA
Pol II ser2 antibody (ab5095, Abcam). DNA was isolated
following reverse cross-linking with QIAquick PCR Purifi-
cation Kit (QIAGEN). ChIP DNA was diluted for qPCR
fifty times. Briefly 3 l of diluted ChIP DNA was used per
reaction, in triplicate with FastStartUniversal SYBRGreen
Master (Roche). Primers are listed in Table 2.
STATISTICS
Data are expressed as mean ± SEM. Statistical analyses
were performed using Student’s t-test for comparison of
means. A probability of less than 0.05 was considered to be
statistically significant.
RESULTS
CAG PSONs significantly down-regulateHTT gene expres-
sion on both mRNA and protein levels
The approach taken was to generate a set of short LNA–
DNA mixmers directed against the transcribed repeat re-
gion in the DNA duplex with the aim of reducing theHTT
mRNA. LNA/DNACAGONs (12-, 13- and 14-mers) were
first designed so that they bind via complementarity to the
HTT DNA template strand. Three of the ONs were syn-
thesized with a PO backbone, while the other three were
PS ONs. In order to test the efficiency of the ONs, we
first used the lipid transfection reagent RNAiMAX as a
delivery vehicle to target primary HD patient fibroblasts
GM04281. Prominent and reproducible HTT knockdown
on both mRNA (Figure 1A) and protein levels (Figure 2)
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Table 2. ChIP-qPCR primers used in the study
Primer # Location Forward sequence Reverse sequence
1 HTT TSS GGTTCTGCTTTTACCTGCGG CTCGGGCCGACTCGC
2 Exon 1 GGTCCAAGATGGACGGC AGCACCGGGGCAATGAAT
3 5′ of CAG repeat ATTGCCCCGGTGCTGAG GGACTTGAGGGACTCGAAGG
4 Gene body (intron 1) GCTCCCTCACTTGGGTCTTC CAAGTTCTCGCCCCAACTCT
5 Gene body (intron 1) GTCAGGCTTGCCAGAATACG TGGGGTTCCGCTAGATGTTT
6 Gene body (intron 1) GAAGACCTTTCTGCTGGGCT TCTCCTTTGTCAAGGCAGCAA
7 Gene body (intron 1) TTCCTATCTGGTGTTTCCCTGAC TTAACACTCGATTAACCCTGACA
8 Gene body (intron 1) TGAGTAAAGACCTCAAGCGAGT GAAGATTTTGGACCTGTTCCCCC
- Exon 30 TGGGGACAGTACTTCAACGC ACCTTGAAAATGTTTCTTCTGGCA
- Exon 67 TCATCAGCAGGATGGGCAAG AGTCAGCAGCCGGTGATATG
could successfully be achieved using the PS ONs. The effi-
ciency of the PS ONs was significantly higher than that ob-
tained by the PO ONs. In order to investigate if the uptake
mechanism could be an explanation for such pronounced
difference in activity, Cy5-labeled ONs of either PS or PO
backbone chemistry were transfected followed by imaging
of the live cells by fluorescence microscopy 4 days after
transfection. The PS ONs showed distinct nuclear localiza-
tion, while the POs were mainly seen in the cytoplasm (Fig-
ure 1B). When HTT protein levels were monitored 7 days
after a single-dose transfection, the same knockdown effi-
ciency of the PS ONs could still be observed (Figure 2C and
D). Control ONs (mismatched ON1 andmismatched ON2)
did not cause any significant reduction in HTT mRNA
(Figure 1A) or HTT protein levels (Figure 2).
Effect of the ON length on the HTT knock-down efficiency
and allele selectivity
We next wanted to test how changing of the CAG PS ON
length would affect HTT down-regulation. Shortening the
ON into a 10-mer completely abolished the effect, while
ONs of 15-, 16-, 18- and 19-mer length significantly reduced
HTT mRNA to levels, similar to the previously evaluated
12-, 13- and 14-mers (Figure 3A). The percentage of re-
maining HTT mRNA ranged from 35% to 50%. Reduced
HTT protein levels were observed 4 days after transfecting
HD patient fibroblasts with the CAG PS ONs (Figure 4A
and B). The reduction in HTT protein levels was significant
compared to all the control ONs tested in the same experi-
ments. A dose response curve was made to one of the ONs
(CAG-16PS) both for mRNA and protein levels (Supple-
mentary Figure S1). Moreover, the knockdown effect on
protein levels lasted for 7 days after single-dose transfec-
tions (Figure 4C andD). There was no significant difference
between the effects on the muHTT versus wtHTT protein
levels using the shorter ONs. However, the longest ON used
in the study (CAG-19PS) showed significantly higher reduc-
tion of themuHTTprotein as compared to the wtHTT after
both 4 and 7 days (Figure 4B and D). To further investigate
whether the effect starts at earlier time points and if it lasts
longer, additional time-points were included in the study
showing that the down-regulation of HTT mRNA started
1 day post transfection (although the effect was weaker and
significantly different from that obtained after 4 days). Effi-
ciency of the ONs even remained up to 10 days, which was
the longest time tested in the study (Supplementary Figure
S2). The selected CAG ONs were also tested in two other
HD fibroblast cell lines: one with a higher repeat number
(151mu/21wt):GM09197 and the otherwith lower number
(44 mu/12 wt): GM04022. Interestingly, the selected CAG
ONs showed efficiency in both cell lines similar to that ob-
tained in the GM04281 (Supplementary Figure S3).
CAG ONs do not affect the expression of other CAG repeat
containing genes
A number of other genes are known to contain tracts of
CAG repeats (27,49). In order to evaluate the potential for
‘off-target’ effects of the examined CAG ONs, we checked
the expression levels of control genes after treating the
GM04281 HD fibroblasts. Western blot analysis showed no
effect for CAG ONs compared to scrambled ONs on the
expression levels of TBP, which contains CAG repeat tracts
of up to 19 repeats in the coding region, FOXP2, contain-
ing a mixed stretch of 40 CAG and CAA repeats (50), or on
the levels of ATN1 having 15 CAG repeats (Supplementary
Figure S4).
CAGONs down-regulateHTTmRNAmore potently as com-
pared to CTG ONs
Knocking down HTT mRNA by a single-stranded ON
can be achieved using either an ON that binds to mRNA
and induces RNase H degradation or an ON that binds
to DNA and blocks its transcription. To exclude that the
HTT mRNA down-regulation effect obtained here could
be due to mRNA binding, we compared our CAG ONs
side by side to ONs complementary to the HTT mRNA,
i.e. CTG ONs. Two 13-mer LNA/DNA CTG control ONs:
CTG-13PS andCTG-13PS gap (Table 1), which differ in the
distribution of LNA and DNA base composition, were de-
signed and tested in GM04281 HD fibroblasts. None of the
control CTGONs caused any reduction of theHTTmRNA
as compared to theCAG-13PS, which significantly did (Fig-
ure 3B). A 19-mer LNA/DNA CTG ON (control CTG-
19PS) resulted in some reduction in HTT mRNA (35%),
as was previously reported (27), and further discussed be-
low. Thus, the remaining HTT mRNA level after transfec-
tion of control CTG-19PS (65%) was significantly higher
than that observed after transfection of CAG-19PS (43%)
(Figure 3B). As expected, and as reported (27), transfection
with the control CTG-19PS ON caused a marked reduction
of HTT protein, with a significantly enhanced effect on the
mutated protein after both 4 and 7 days (Figure 5). This ob-
servation indicates that the investigated CAG ONs, which
5158 Nucleic Acids Research, 2017, Vol. 45, No. 9
Figure 1. CAG phosphorothioate (PS) oligonucleotides (ONs) reach the nucleus and significantly down-regulate Huntington (HTT) gene expression on
mRNA level. LNA/DNA CAG 12-, 13- or 14-mer ONs, with either PS or PO backbone, were transfected at 100 nM concentration after formulation with
the commercial cationic lipid RNAiMAX into human HD patient fibroblasts GM04281. Four days post treatment, the cells were lysed and RNA was
isolated and further analyzed by quantitative reverse transcriptase multiplex PCR (qRT-PCR). (A) Shows the HTT mRNA levels after each treatment
normalized toHPRT as a housekeeping reference gene. Significant differences were found between CAG-12PS versus CAG-12PO (P < 0.05), CAG-13PS
versus CAG-13PO (P < 0.0001) and CAG-14PS versus CAG-14PO (P < 0.01). Mismatched ON1 and mismatched ON2 were used as control ONs and
were significantly different from all constructs except for the 13PO and 14PO (significance levels shown in the figure). (B) Shows the uptake behavior of
Cy5 labelled ONs (PS or PO backbone) after transfection into GM04281 fibroblasts as detected by fluorescence microscopy of live cells.
down-regulate HTT on the mRNA level, are working via a
mechanism that does not involve binding to mRNA, but is
instead compatible with an effect caused by binding to the
HTT gene.
UV melting measurements
To further confirm that the CAG ONs do not bind to the
RNA sense sequence, Tm was measured for the combina-
tion of CAG-13PS and RNA (19-mer CAG ON) and com-
pared to that of control CTG-13PS and RNA. The RNA
used as target was a 19-mer CAG ON and the analysis
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Figure 2. CAG PS ONs significantly down-regulateHTT gene expression on protein level. LNA/DNACAG 12-, 13- or 14-mer ONs, with either PS or PO
backbone, were transfected at 100 nM concentration after formulation with RNAiMAX into human HD patient fibroblasts GM04281. (A and B) Four
days or (C and D) seven days post treatment, cells were lysed and western blots were performed to detect the HTT protein with its two isomers: mutant
HTT (muHTT) and wild-type (wtHTT). Importin 7 was used as a housekeeping control. (A) Shows a representative western blot gel for the 4 days-time
point, while (C) shows a representative gel for 7 days. Results from three replicate experiments were quantified and plotted in (B) and (D) for the 4 and
7 days data, respectively. There were significant differences between the total (mutant + wild-type) remaining HTT protein amounts after the treatment
with: CAG-12PS versus CAG-12PO (P<0.01 and P< 0.01, for 4 and 7 days), CAG-13PS versus CAG-13PO (P< 0.0001 and P< 0.05, for 4 and 7 days),
CAG-14PS versus CAG-14PO (P < 0.01 and P < 0.05, for 4 and 7 days). Mismatched ON1 and ON2 were used as controls and there was no significant
difference between them, whereas total HTT protein levels obtained by all PS ONs were significantly different from that obtained by mismatched ON1
(significance levels shown in the figure).
showed no evidence of any interaction between the CAG-
13PS and the RNA, since there was no shift in theTm curve
(Figure 6E). On the other hand, control CTG-13PS com-
bined with the RNA target sequence markedly shifted Tm
> 20◦C indicating binding and interaction on theRNA level
(Figure 6C). In addition, the CAG-19 ON showed no bind-
ing to the RNA ON (Figure 6G). Due to the large shift in
Tm (>95◦C) that the control CTG-19 ON together with the
RNA would generate, this combination was never tested.
Of the different ONs, only the target 19-mer CAG RNA
ON alone (Figure 6A) showed an increased Tm (around
62◦C), indicating self-interactions not present in the CAG-
13, CAG-19 or control CTG-13 ONs.
CAG ONs bind to and invade dsDNA as evidenced in a re-
striction enzyme assay
To further investigate the proposed dsDNA strand-invasion
mechanism, we set out to test if the CAG ONs could bind
to and invade supercoiled dsDNA. To study this, we used
restriction enzymes cleaving near the ON binding sites. The
change in the cleavage pattern resulting from ON-mediated
steric blocking of enzyme activity has previously been de-
scribed in the context of triple-helix formation (51,52). Plas-
mid 1735-1, which contains a repeat region consisting of 72
CAG triplets, was hybridized to CAG ONs (13-, 14-, 15- or
19-mers) for 72 h at 37◦C. This plasmid contains AvrII and
HindIII restriction enzyme sites, which were used in com-
bination to linearize the plasmid followed by analysis using
gel electrophoresis (Figure 7). HindIII cleaves the plasmid
at two sites, one located 40 bp upstream of the trinucleotide
repeat region and the other 742 bp 3′ of this region. AvrII
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Figure 3. (A) Effect of the ON length on theHTTmRNAknockdown effi-
ciency. LNA/DNACAG10- to 19-mer PSONswere transfected at 100 nM
concentration into GM04281 human HD fibroblasts using RNAiMAX.
Four days post treatments, cells were lysed and RNA was isolated and an-
alyzed by qRT-PCR using primers and probes for HTT and for HPRT as
a housekeeping reference gene. HTT mRNA levels after treatment with
CAG-12, -13, -14, -15, -16, 18- and -19 were all significantly reduced as
compared to CAG-10PS and to all themismatched and scrambled controls
(significance levels between each ON and the scrambled ON1 are shown in
the figure). CAG-15PS differed significantly as compared to CAG-12PS,
CAG-14PS and CAG-18PS. CAG-16 PS differed also significantly as com-
pared to CAG-14PS and CAG-18PS. No other significant differences were
found between the ONs from 12 to 19-mer in HTT mRNA knockdown
levels. (B) CAG ONs down-regulate HTT mRNA more potently as com-
pared to control CTG ONs. The 13- and 19-mer ONs of either CAG or
CTG sequence were transfected into HD fibroblasts GM04281 for 4 days
and the remaining HTT mRNA levels were assessed using q RT-PCR. A
significant difference was found between the remaining HTT mRNA lev-
els after CAG-19PS versus control CTG-19PS treatment (P < 0.01) and
they were both significantly different from the control ON (mismatched 1)
(P < 0.001 and P < 0.001). CAG-13PS effect was significantly different
from mismatched1 ON (P < 0.00001). CTG-13PS and CTG-13PS control
ONs did not show any significant difference compared to the control mis-
matched ONs used in the study.
cuts at a site located only a single bp after the trinucleotide
repeat region. Together they are expected to generate two
fragments; however, as seen in Figure 7B, the cleavage by
AvrII is hindered by the presence of a CAG ON. More-
over, the longer the CAG ON used, the less effective was
AvrII digestion, as indicated by the weaker band generated
with AvrII and the appearance of the band corresponding
to HindIII cleavage only (Figure 7). Our interpretation is
that this is due to the fact that a long CAG ON would have
a greater probability to interfere with AvrII cleavage due to
steric hindrance. The weaker bands seen in the gel (marked
by a ’*’), which also follow this pattern, we believe originate
from a different plasmid sub-clone, which exists as a small
fraction lacking a part of the 72 CAG region due to repli-
cation errors during plasmid preparation (Figure 7A).
CAGONs significantly reduce serine 2 phosphorylated RNA
Pol II occupancy across the HTT gene
In order to confirm the CAGONs binding to chromosomal
DNA, we set out to investigate first whether the reduction
in HTT gene expression was associated with epigenetic in-
activation of the HTT promoter or reduced promoter ac-
tivity. We performed ChIP-qPCR for active histone marks
H3K4me3 and H3K27ac, which are associated with the
transcription start site (TSS) of actively transcribed genes
(53). Primers were designed across the HTT gene 5′ region
using ChIP-seq data from the ENCODE project to map
to locations associated with active histone modifications
across the HTT gene in normal conditions (Supplemen-
tary Figure S5A). No significant loss of either H3K4me3
or H3K27ac was observed after treatment with CAG-19PS
compared to scrambled ON, suggesting the CAG ON’s
function to be independent of promoter activation and si-
lencing (Supplementary Figure S5B and C). Given that the
CAG ON targets the first exon of the HTT gene, down-
stream of the TSS and Pol II initiation site, we hypothesized
that the CAG ONmay influence Pol II elongation in trans-
fected cells. This can be examined through measuring ser-
ine 2 (ser 2) phosphorylated RNA Pol II occupancy (54).
Serine 2 phosphorylation of RNA Pol II occurs during pro-
ductive elongation of Pol II following initiation and Pol II
ser2 occupancy in the 3′ exons of genes is correlated to gene
expression and elongation rates. PCR primer positions rel-
ative to RNA Pol II ser2 occupancy across theHTT gene in
human cell lines is shown in Figure 8A. Interestingly, CAG-
19PS did indeed reduce the 3′ occupancy of Pol II ser2 in
the HTT gene, while showing a slight increase of Pol II at
the 1st exon upstream of the transcribed trinucleotide re-
peat region (Figure 8B). It was observed that Pol II ser2
occupancy was higher upstream of the transcribed repeat
region, but significantly reduced in the middle and 3′ end
of the gene at exons 30 and 67 respectively. This provides
proof that the mechanism ofHTTmRNA reduction is me-
diated through a direct effect on transcription at the level of
RNA Pol II elongation suggesting that binding of the ON
in living cells poses a barrier toHTT gene transcription. No
differences were observed at control loci in the last exons of
the PRDM1 or ACTB genes (Figure 8C).
CAG ONs can be delivered to patient fibroblasts by peptide
and gymnotic delivery
PepFect 14 (PF14), a recently developed cell-penetrating
peptide (CPP) (55), was tested as a delivery vehicle for the
LNA/DNA CAG ONs. ON/PF14 formulations at molar
ratio 1:5 resulted in similar activity as that obtained by
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Figure 4. Effect of the ON length on the HTT protein knockdown efficiency and allele selectivity. LNA/DNACAG 10- to 19-mer PS ONs were transfected
at 100 nM concentration into GM04281 human HD fibroblasts using RNAiMAX. Four or seven days post treatments, cells were lysed and western blots
were performed to detect the HTT protein with its two isomers: muHTT and wtHTT. Importin 7 was used as a housekeeping control. (A) Shows a
representative western blot gel for the 4 days-time point, while (C) shows a representative gel for 7 days. Results from three replicate experiments were
quantified and plotted in (B) and (D) for the 4 and 7 days data, respectively. Total HTT protein levels remained after treatments with ONs (from 12 to
19-mers) were significantly different from all control ONs tested in the study. Significance levels between each CAG ON and the control ON (mismatched
1) are shown in panel (B) and (D). No significant difference was found between the control ONs used in the study. A significant difference was found
between the remaining muHTT and wtHTT protein levels 4 and 7 days after treatment with CAG-19PS (P < 0.01 and P < 0.05, respectively).
RNAiMAX formulations with CAG-13PS to 19PS (Figure
9A). PF14/CAG-12PS formulation was less efficient than
that with RNAiMAX. Of great interest for CNS delivery is
the ability of the ONs to enter the cells without any delivery
agent, a phenomenon sometimes referred to as ‘gymnosis’
(46). ONs were added to the GM04281 HD fibroblasts at a
concentration of 1 Mwithout using transfection reagents.
Similar and significant levels of HTT mRNA knock-down
was achieved with CAG-PS 13-, 14-, 15-, 16-, 18- and 19-
mers when compared to control ONs while the 12-mer was
less efficient (Figure 9A). Interestingly, the control CTG-
19PS blocking effect onHTTmRNA could not be detected
using PF14 or gymnotic delivery (Figure 9A), whereas, sim-
ilar to the data presented in Figure 3B, RNAiMAX induced
a reduction. An siRNA designed against HTT mRNA was
used as a positive control for the down-regulation. The
siRNA was highly efficient only after transfection reagent-
aided delivery, but not in gymnosis. CAG-PS ONs (13-
and 14-mers) showed markedly and significantly higher ef-
ficiency compared to PO ONs when formulated with PF14,
similar to what was seen with RNAiMAX formulations
(Figure 9B). Gymnosis of CAG-ONs having a PO back-
bone unexpectedly caused death of the fibroblasts grown for
7 days following the addition of theONs. In contrast, the PS
ONs were biocompatible, with fibroblasts showing no signs
of toxicity by visual inspection (data not shown).
Effect of ON chemical modifications on efficiency
We finally wanted to assess how other types of chemi-
cal modification of the ONs could affect the silencing ef-
ficiency. CAG-14PS-OMe is a 14-mer CAG ON, with all
DNA nucleotides exchanged for 2′-O-methyl RNA (Table
1). CAG-14PS-gly is another 14-mer CAG in which four
LNA-based cytidines were exchanged by 5-methylcytosine-
2′-glycylamino-LNAs (Table 1). Using RNAiMAX, parent
CAG-14PS showed significantly better down-regulation ef-
ficiency than the two ONs with the modifications. However,
gymnotic delivery of the three ONs at 1 M gave the same
activity (Figure 10A). We then generated a dose-response
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Figure 5. CAG ONs versus control CTG ONs in HTT protein down-regulation efficiency. The 13- and 19-mer ONs of either CAG or CTG sequence were
transfected into HD fibroblasts GM04281 for 4 days or 7 days followed by cell lysis and western blots. (A) and (C) show representative western blot gels
for the 4 and 7 days data, respectively. Quantification of western blot gels is shown in (B) for the 4 days and (D) for the 7 days results. Significant difference
was found between the remaining muHTT and wtHTT protein levels 4 and 7 days after treatment with CAG-19PS (P <0.01 and P < 0.05) and with
control CTG-19PS (P < 0.01and P < 0.05). No other significant difference was found between muHTT and wtHTT after treatment with any other ON.
Total HTT protein was significantly reduced after treatment with CAG-19PS, control CTG-19PS and CAG-13PS as compared to the mismatched controls
(significance levels between each ON and mismatched 1 are shown in the panels B and D). Control CTG-13PS and 13PSgap were not significant compared
to the mismatched control ONs.
curve for gymnosis of the three ONs, which revealed that
a 50% knocking down of HTT mRNA can be achieved
after gymnosis at 0.5 M of the parent 14-mer, while the
two modified 14-mers need to be present at almost double
this concentration in order to give a 50% reduction (Fig-
ure 10B). There were slight differences (not significant) in
the dose-response curves, demonstrating that adding these
modifications (in terms of type and number of modified
bases) did not significantly improve the down-regulation ef-
ficiency of the CAG ON.
DISCUSSION
In this report, we are showing for the first time the pos-
sibility to down-regulate HTT on both mRNA and pro-
tein levels by single-stranded LNA/DNAONs targeting the
template strand of the trinucleotide repeat region. In con-
trast to antisense ONs targeting RNA, anti-gene ONs are
designed for sequence-specific targeting of the chromoso-
mal dsDNA. Such binding has previously been shown us-
ing triplex forming oligonucleotides (56) or by ONs with
the ability to strand invade into dsDNA, as further dis-
cussed below. Since its development (57,58), and thanks to
its great stability and high target affinity and recognition
properties, LNA has been exploited for several applications
including the design of antisense ONs working via different
mechanisms (58). Furthermore, LNA-based ONs, namely
Zorro-LNA and bisLNA, were proven to hold high ca-
pacity of strand-invasion into dsDNA (45,57,59–62). Short
LNA/DNA ONs were also shown to bind as anti-gene
agents and block gene expression (63).
We herein aimed at investigating the ability of short
LNA/DNA ONs (ranging from 10- to 19- mers) to strand-
invade into theHTT gene and down-regulate its level of ex-
pression. The ONs were designed with a CAG sequence, so
that they would bind via complementarity to the CTG re-
peat sequence, i.e. to the template strand of the repeat re-
gion in theHTT gene. Since the anti-gene technology is far
less explored in literature than the antisense, little is known
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Figure 6. UV melting profiles of CAG, CTG and target RNA ONs. All graphs show the Tm curves (marked ‘Tm’ in the figure) together with the second
derivative in the background. (A) target RNA alone, (B) CTG13 alone, (C) RNA+CTG13, (D) CAG13 alone, (E) RNA+CAG13, (F) CAG19 alone and
(G) RNA+CAG19. Only CTG13 is capable of binding the target RNA and shift the Tm above the baseline of the RNA ON alone.
Figure 7. Binding of CAG ONs to target plasmid DNA visualized by restriction digestion and PAGE. Panel (A) shows the gel lanes with control and
ON-hybridized plasmids digested with HindIII and AvrII, as indicated. * Denotes bands believed to originate from a subclone containing a truncated
repeat region. Panel (B) schematically illustrates the mechanism by which the ONs hinder the cleavage by AvrII. Upper panel shows the cleavage pattern
when no part of the binding ON is interfering with AvrII cleavage. Lower panel shows that longer ON binding randomly increases the probability of steric
blocking of the Avr-site.
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Figure 8. Serine 2 phosphorylated RNA Pol II occupancy across theHTT gene is reduced upon transfection with CAG-19PS (A) UCSC genome browser
image demonstrating RNA Pol II ser2 occupancy across the HTT gene. Primer positions at exon 1 upstream of the CAG repeat and at exons 30 and the
last exon, 67, are indicated. (B) RNA pol II occupancy is significantly increased at exon 1 of the HTT gene immediately upstream of the CAG repeat (*P
< 0.05) and reduced at the 3′ exons 30 and 67 (*P < 0.05, ***P < 0.001). (C) No difference is observed at control loci in the last exons of the PRDM1 or
ACTB genes.
about how different ON structures and chemical modifica-
tions affect the binding efficiency.
Therefore, we investigated a few different types of ONs
as well as various delivery methods. Collectively we found
that the effect was not limited to a single ON chemistry
or to a single delivery method. We started out by testing
the two main backbone chemistries, commonly used for
building antisense ONs: PO and PS backbones, and assess-
ing the effect exerted by both in the anti-gene context. In-
terestingly, only transfection of PS ONs and not POs, re-
sulted in a prominent and significant knocking-down of
HTT mRNA and protein in HD patient fibroblasts. The
fluorescencemicroscopy images displayed amarked nuclear
uptake of the PS ONs versus the POs, which mostly stained
the cytoplasm. Previous reports have demonstrated that PS
ONs could bind to nuclear proteins (64,65), which would
explain the uptake behavior observed here. Moreover, in-
teractions of PS ONs with a number of other intracellular
proteins have been recently addressed (66), suggesting that
a PS backbone is required for the CAGONs to be effective.
Nucleic Acids Research, 2017, Vol. 45, No. 9 5165
Figure 9. CAG ONs can be delivered to the patient fibroblasts by pep-
tide and gymnotic delivery. (A) LNA/DNA CAG 10- to 19-mer PS ONs
were transfected at 100 nM into GM04281 human HD fibroblasts using
RNAiMAX or PF14 at molar ratio 1:5 (ON: peptide) or were added to
the cells at 1 Mwithout transfection reagents (gymnosis). Control CTG-
19PS, mismatched, scrambledONs and siRNAwere used as controls. Four
days post treatments, the cells were lysed and RNA was isolated and an-
alyzed by q RT-PCR using primers and probes for HTT and HPRT as a
housekeeping reference gene. Significant differences were found between
CAG-19PS and CTG-19PS using all delivery methods (RNAiMAX (P <
0.01), PF14 (P< 0.01), gymnosis (P< 0.0001)). All ONs ranged from 12 to
19-mer delivered by gymnosis significantly reduced HTT mRNA (signifi-
cance levels are shown in the graph). (B) LNA/DNA CAG 12-, 13- or 14-
mer ONs with either PS or PO backbone were transfected at 100 nM con-
centration after formulation with RNAiMAX or with PF14 at molar ratio
1:5 (ON: peptide) into humanHDpatient fibroblastsGM04281. Therewas
no significant (ns) difference between RNAiMAX and PF14 formulations
with CAG-13PS and CAG-14PS. For PF14 formulations, the mismatched
controls differed significantly from all treatments except for CAG-12PS,
CAG-12PO and CAG-13PO (significance levels for all ONs compared to
mismatched 1 are shown in the figure).
Figure 10. Effect of ON chemical modifications on efficiency. (A) CAG-
14PS, CAG-14PS-OMe and CAG-14PS-gly were transfected at 100 nM
into GM04281 human HD fibroblasts using RNAiMAX, or were added
to the cells at 1 M concentration without transfection reagents (gymno-
sis). Four days post treatments, the cells were lysed and RNA was isolated
and analyzed by qRT-PCR using primers and probes forHTT andHPRT.
Significant differences were found between mRNA levels after treatment
with: CAG-14PS versus CAG-14PS-OMe (P < 0.05), CAG-14PS versus
CAG-14PS-gly (P< 0.01). Significance levels of all ONs compared to mis-
matched 1 ON are shown in the figure. (B) A dose response curve for the
three ONs after gymnosis with increasing concentrations of each ON in
GM04281.
The down-regulation achieved by the CAGONs, on both
HTT mRNA and protein, can be directly expected from
their sequence, since they should bind to the complemen-
tary DNA strand in the gene. In theory, mRNA, which is
a CAG sequence itself, can therefore not be a target for
a CAG ON. This was verified by the thermal UV melt-
ing measurements, which clearly demonstrated the differ-
ence between the CAG and CTG ONs, when incubated
with the CAG RNA and, how that affected the shift in
Tm values (Figure 6) as well as by gel shift experiments
(data not shown). To further exclude the probability that
our CAG ONs could bind the sense RNA sequence, we
compared them with CTG ONs by transfection into HD
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patient fibroblasts. In fact, CTG ONs were earlier used to
down-regulate HTT on the protein level via binding to the
HTTmRNA and blocking its translation (27). Transfection
of CTG-19PS resulted in some mRNA down-regulation,
whichmight be explained by the possibleRNaseHdegrada-
tion of mRNA due to the ON sequence that alternates one
LNA with two DNA bases (27). This down-regulation was
still not efficient; confirming that a gap of at least fiveDNAs
is needed in order to induce a decent RNase H degradation
(67). In contrast, the HTT mRNA knockdown obtained
by CAG-19PS was significantly greater, which strongly sug-
gests that mRNA degradation is not the mechanism by
which the CAGONs affect the mRNA level. Both CAG-19
and CTG-19 showed pronounced protein down-regulation,
which was significantly selective for the muHTT protein af-
ter 4 and 7 days (Figure 5). The CTG-13PS control ONs
did not induce any reduction of the HTT mRNA. Unlike
the CTG-19PS, none of CTG-13PS ONs caused any reduc-
tion of the HTT protein, implying the need for a certain
length of the antisense ONs to achieve steric blocking of the
mRNA and impair its translation. Conversely, CAG-13PS
produced a marked and highly significant down-regulation
of bothmRNAand protein, indicating the possibility to tar-
get DNA with rather short ONs and still obtain an effect.
This is advantageous when addressing formulation and de-
livery aspects of ONs for pharmaceutical applications.
Earlier reports have shown that dsDNA containing CAG
repeats, after strand-separation, can adopt a specific sec-
ondary structure due to intra-strand, semi-complementary
base-pairing (68,69). Since it was unclear whether the ex-
amined CAG ONs could bind to these regions, we decided
to investigate that further. Steric blocking of restriction en-
zyme sites has been used previously as a tool to assess ON
sequence-specific binding of dsDNA through the formation
of a triplex structure (51,52). Here, we show that CAG-ONs
could inhibit the AvrII cleavage of a DNA plasmid contain-
ing 72 trinucleotide repeats, where the cleavage site of AvrII
is located one base-pair outside of the repeat region. The
longer the ON, the higher was the inhibition of cleavage at
this site. This is expected, since shorter ONs would presum-
ably hybridize too weakly if they would extend outside the
target site, and demonstrates that the CAG-ONs could in-
deed bind to the repeat region in dsDNA. Furthermore, in
a study performed by Chung et al. (70), a natural antisense
transcript consisting of exon 1 and 2 of the HTT gene was
identified. However, it was shown in the same study that
down-regulating this transcript would rather lead to an in-
crease in the endogenous HTT transcript levels, suggesting
that this transcript is not the target of the investigated CAG
ONs.
In order to confirm the DNA binding of the CAG
ONs, we investigated the possible occurrence of any epige-
netic changes. We first checked the active histone markers:
H3K4me3 and H3K27ac, which are associated with TSS of
actively, transcribed genes. Level of these markers did not
significantly change by the CAG ON treatment, which can
be explained by the fact that the CAG ON’s effect is in-
dependent of promoter activation and silencing. However,
a trend towards increased histone acetylation (P = 0.67)
was still observed at the region immediately upstream of
the transcribed trinucleotide repeat sequence in cells trans-
fected with the HTT gene targeting ON (Supplementary
Figure S5). We hypothesized that this may be linked to
slower transcriptional elongation rate at this region of the
HTT gene leading to slight hyper-acetylation of chromatin
upstream of the transcribed repeats.
Since the CAG ONs are targeting exon 1 downstream of
the polymerase initiation site, we reasoned that their bind-
ing wouldmore likely affect the polymerase elongation. The
occupancy of Pol II ser2 is correlated to active transcrip-
tional elongation and is therefore correlated with gene cod-
ing regions of actively transcribed genes (71). The signifi-
cant reduction in ser2 occupancy by CAG-19PS compared
to a scrambledON in both themiddle and 3′ end of theHTT
gene clearly suggests an effect on theDNA level. Altogether,
these results provide strong evidence for the anti-genemech-
anism as the mode of action of our designed CAG ONs.
Since delivery is a hurdle for most of the ON-based ther-
apeutics, we sought to test methods, other than the com-
mercial cationic lipids, that can be further used for in vivo
applications of the CAGONs. PF14 is a recently developed
CPP which shows pronounced efficiency as a vehicle for
a number of ON categories, such as splice switching ONs
(55) and siRNAs (72); however, it was never tested for de-
livery of anti-gene ONs. Interestingly, similar efficiency was
achieved for CAGONs ranging from 13- to 19-mers as com-
pared to that obtained with RNAiMAX formulations of
the same ONs. A number of ONs designed for treatment
of HD have been delivered as naked ONs into the brain
(26,31). Gymnosis is a technique that has been recently used
to simulate the in vivo injection of non-formulated ONs but
in cell culture models (73). Our LNA/DNA CAG PS ONs
showed marked efficiency after gymnosis at a relatively low
dose (sub-micromolar range) in humanHDfibroblasts. An-
tisense ONs built of chemically modified nucleotides such
as LNA and peptide nucleic acids have previously shown
efficiency after gymnosis in cell cultures at similar concen-
trations (74).
Chemical modification of ONs is commonly used to im-
prove their binding and pharmacokinetic properties, such
as the 2′-O-Me RNAmodification (75,76). Interestingly, we
found here that exchanging all DNA bases in the CAG-
14PSwith 2′-O-methylRNAdid not improve theONdown-
regulation efficiency. It was previously reported by Wengel
et al. that the 2′-O-methyl RNA interaction with an RNA
target is stronger than with a DNA target based on Tm
measurements, which could help to explain the reduced ef-
ficiency of the tested ON (77). 2′-Glycylamino-LNA is an-
other recently developed modification carrying a positively
charged glycyl group at the N2′-position enhancing duplex
stability (78), but did not show any improvement in the anti-
gene context. It is plausible that these delivery methods are
not optimal for positively charged modified ONs, and fur-
ther optimization might be needed. It is also possible that
such ONs behave differently when administered in vivo.
A number of different ON-based strategies have been
attempted with the goal of reducing the muHTT expres-
sion levels. Targeting mRNA is a very appealing concept
because of the wide experience of such methods. In addi-
tion, gene targeting can be as well achieved at the transcrip-
tional level using a number of techniques such as zinc fin-
ger nucleases, the recently developed CRISPR/Cas systems
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(Shin, J.W. et al. (2016) Permanent inactivation of Hunt-
ington’s disease mutation by personalized allele-specific
CRISPR/Cas9. Hum. Mol. Genet.), or simply by dsDNA
strand-invadingONs such as the LNA/DNAmixmers eval-
uated in this study. Zinc finger nucleases and CRISPR/Cas
induce permanent changes in the DNA, but are difficult to
deliver. Strand-invading ONs potentially cause a more sus-
tained down-regulation of HTT expression as compared to
ONs targeting RNA. Each strategy has its pros and cons
and therefore, it can be relevant in the future to consider
combined HD therapies formed of ONs working by dif-
ferent mechanisms, since this could reduce toxicity and en-
hance efficacy.
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